Germany Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Germany Breast Cancer Therapeutics Market Analysis

$ 3999

For the forecasted year 2022-2030, the Germany breast cancer therapeutics market is expected to see growth from $666 Mn in 2022 to $1,546 Mn in 2030 with a CAGR of 11.1%. Introduction of new screening programs and government initiatives to increase awareness of breast cancer and major market drivers in Germany. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the leading companies in Germany breast cancer therapeutics market are Janssen, GSK, and Merck & Co., Inc.

ID: IN10DEPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Parul Choudhary

Buy Now

Germany Breast Cancer Therapeutics Market Executive Analysis

The Germany breast cancer therapeutics market size is at around $666 Mn in 2022 and is projected to reach $1,546 Mn in 2030, exhibiting a CAGR of 11.1% during the forecast period. In 2021, Germany's GDP was 12.8% dedicated to healthcare. Germany's current healthcare costs were covered by transfers and government subsidies in 2020. This reflects an increase of $17.4 Bn, or 31.5%, from the prior year, according to the Federal Statistical Office (Destatis). Government transfers and subsidies thus accounted for 15.7% of the $4,609 Bn in current health expenditure, an increase of 3.0% % in age points from the previous year.

In Germany, 68,950 women received a breast cancer diagnosis, and 18,570 of them passed away from the illness in 2016. Due to population aging and changes in reproductive behavior, an increase in breast cancer cases is anticipated in Germany. Every two years, all women between the ages of 50 and 69 are invited to a mammogram as part of the German Mammographic Screening Program (MSP). The program's goal is to decrease breast cancer-related mortality through early cancer detection. According to revised German guidelines, screening decisions should be made based on an individual's risk for women under the age of 50 and over the age of 70. Women ages 40 to 49 who are at moderate breast cancer risk should be screened by ultrasound and mammography.

germany breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Over the projected period, the breast cancer therapy market in Germany is expected to rise as a result of rising alcohol use among German women, rising obesity rates, and increased radiation exposure risks. The formulation and implementation of new screening programs, as well as the efforts made by the German government to raise awareness of therapeutic interventions and host free camps, are projected to be key drivers of the growth of the German market for breast cancer therapeutics.

Market Restraints

One of the main obstacles to German market expansion is the high cost of breast cancer treatments. Monoclonal antibodies (mAb), one of the newest targeted treatments, add to the cost of treating breast cancer. Because creating monoclonal antibodies requires complex techniques, these treatments are expensive. In Germany, the market expansion is further limited because of inadequate insurance coverage for breast cancer.

Competitive Landscape

Key Players

Boehringer Ingelheim (DEU)
Novartis (DEU)
Janssen (DEU)
GSK (DEU)
Merck & Co., Inc.
Bristol-Myers Squibb
Roche
Bayer
Novo Nordisk

Healthcare Policies and Regulatory Landscape

All people who are covered by the Statutory Health Insurance (SHI) system in Germany are covered for breast cancer treatment. Breast cancer patients can also get assistance from the German Cancer Society (Deutsche Krebsgesellschaft) and the German Cancer Aid (Deutsche Krebshilfe), both of which provide offer financial aid and information on available treatments. The German Cancer Society (Deutsche Krebsgesellschaft) and the German Cancer Aid (Deutsche Krebshilfe) standards are typically used to determine the reimbursement policy for breast cancer therapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.